Method for treating hearing loss

a hearing loss and hearing technology, applied in the direction of salicyclic acid active ingredients, organic active ingredients, pharmaceutical delivery mechanisms, etc., can solve the problems of hearing impairment, kidney damage, loss of balance,

Active Publication Date: 2017-04-25
RGT UNIV OF MICHIGAN
View PDF39 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]The subject disclosure provides a method of treating hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and / or resveratrol.

Problems solved by technology

Particularly problematic side effects from antibiotic treatment include kidney damage, loss of balance, and hearing loss attributable to antibiotic treatment such as aminoglycoside or glycopeptide antibiotic treatments.
The damaging side effects of many aminoglycoside antibiotics were first reported in the 1940s, and the damaging side effects have long been an impediment to use of aminoglycoside antibiotics.
Aminoglycoside antibiotics cause permanent deficits in the vestibular system (balance) and irreversible cell death in the cochlea, resulting in hearing impairment.
While the damaging side effects of aminoglycoside antibiotics, in particular, have impeded their use, it has not eliminated their use.
However, in countries in which there are fewer alternative drugs and monitoring is less rigorous or non-existent, side effects associated with aminoglycoside antibiotic treatment is more prevalent.
Given the generally lax monitoring and the high incidence of side effects associated with aminoglycoside antibiotic treatment in developing countries, poor patient compliance in completing proscribed aminoglycoside antibiotic treatment is common, contributing to the development of drug-resistant strains of tuberculosis.
However, it is clear from the literature that great variability is found in the efficacy of some of the agents to reduce the damaging side effects of aminoglycoside antibiotics.
For example, allopurinol is ineffective in reducing gentamicin-induced ototoxicity, but is effective in reducing noise-induced hearing loss.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating hearing loss
  • Method for treating hearing loss
  • Method for treating hearing loss

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0094]The method of treating side effects of antibiotic treatment with the composition of the present disclosure is again performed on guinea pigs (normal hearing, male, pigmented). Six guinea pigs are subject to antibiotic administration and treatment with the composition of the present disclosure. The guinea pigs were fed with a chow containing the composition including beta-carotene, vitamin C, vitamin E, and magnesium in the amounts shown in Table 3 for 10 days prior to administration of a first dosage of gentamicin antibiotic, and were fed the same chow every day for 41 days. The guinea pigs consumed a normal diet sufficient to allow them to gain weight. Gentamicin was administered to the guinea pigs subcutaneously once a day for 16 consecutive days after administration of the first dosage of the gentamicin. Body weights were monitored and the guinea pigs were observed for clinical signs of systemic toxicity. Guinea pigs losing weight were treated with subcutaneous saline and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
test frequenciesaaaaaaaaaa
weightaaaaaaaaaa
body weightaaaaaaaaaa
Login to view more

Abstract

A method of treating hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.

Description

RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 13 / 091,931, filed Apr. 21, 2011, which is a continuation-in-part of U.S. application Ser. No. 12 / 761,121 filed on Apr. 15, 2010, which is a continuation-in-part of U.S. application Ser. No. 11 / 623,888, filed on Jan. 17, 2007. U.S. application Ser. No. 11 / 623,888 is now U.S. Pat. No. 7,951,845, and U.S. application Ser. No. 11 / 623,888 claims priority to and all advantages of U.S. Provisional Patent App. Ser. No. 60 / 760,055, which was filed on Jan. 19, 2006. This patent application is also a continuation-in-part of U.S. application Ser. No. 13 / 091,931 filed on Apr. 21, 2011, which is a continuation of U.S. application Ser. No. 11 / 623,888 filed on Jan. 17, 2007. U.S. application Ser. No. 11 / 623,888 is now U.S. Pat. No. 7,951,845, and U.S. application Ser. No. 11 / 623,888 claims priority to and all advantages of U.S. Provisional Patent App. Ser. No. 60 / 760,055 filed on Jan. 19, 2006.T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K33/06A61K31/245A61K31/375A61K33/00A61K31/60A61K31/07A61K45/06A61K31/05A61K31/341A61K31/355
CPCA61K31/05A61K31/355A61K31/375A61K33/06A61K9/0019A61K9/0053A61K31/07A61K31/585A61K2300/00A61K31/341A61K33/00A61K45/06
Inventor MILLER, JOSEF M.GREEN, GLENN E.LEPRELL, COLLEEN G.
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products